1. Introduction {#s0005}
===============

Hepatitis E virus (HEV) is a feco-orally transmitted pathogen and one of the most common causes of acute hepatitis worldwide. Although the virus was already identified in 1983 ([@b0040]), many of its epidemiological and clinical features are becoming clear just recently. HEV is responsible for both acute outbreaks in developing countries and sporadic cases worldwide and is more and more being recognized as a problem in the transplant setting ([@b0405], [@b0675]). Although most infections are self-resolving, hepatitis E is characterized by a high mortality in pregnant women and can lead to chronic infections in immunocompromised patients. A vaccine has recently been approved for the Chinese, but not for other markets ([@b0925]). Current therapeutic options (i.e. ribavirin and interferon-α) have severe side effects and treatment failure has been reported. It may be important to have potent and safe inhibitors of HEV replication at hand to rapidly contain outbreaks and to treat immunodeficient patients.

In this review, a general introduction to HEV is presented, followed by an overview of different potential antiviral targets and currently available methods for drug testing. Directions for developing antivirals against the HEV will be suggested.

2. Hepatitis E virus {#s0010}
====================

2.1. Genome structure {#s0015}
---------------------

HEV has a capped positive-sense single-stranded RNA genome that comprises a 5′ untranslated region (UTR), open reading frames (ORF) 1--3 and a 3′ UTR followed by a polyA-tract (see [Fig. 1](#f0005){ref-type="fig"} ). ORF1 encodes the non-structural proteins and contains methyltransferase, protease, macrodomain, helicase and RNA-dependent RNA polymerase (RdRp)-encoding sequences ([@b0495]). Between the protease and the macrodomain, a hypervariable region containing a proline-rich hinge was found ([@b0785]). The overlapping ORFs 2 and 3 are translated from a single subgenomic RNA into the structural proteins ([@b0300]). ORF2 encodes the 660-aa capsid protein that consists of a shell domain (S), a middle domain (M, also called P1) and a protruding domain (P, also called P2) ([@b0305], [@b0895]). The protein translated from ORF3 is 114 aa in length, is phosphorylated ([@b0905]) and unique to HEV and closely related viruses.Fig. 1Organization of the HEV genome. Non-structural proteins are translated from ORF1 while the ORF2 and ORF3 structural proteins are translated from a single subgenomic RNA. UTR, untranslated region; Y, Y-domain; PCP, papain-like cysteine protease; HVR, hypervariable region; X, macro domain; RdRp, RNA-dependent RNA polymerase.

2.2. Replication cycle {#s0020}
----------------------

Although understudied, the HEV replication cycle seems typical for a single-stranded RNA virus of positive polarity (see [Fig. 2](#f0010){ref-type="fig"} ). The virus particle first binds to heparan sulfate proteoglycans (HSPGs) on the host cell membrane ([@b0400]), transfers to its (unknown) cellular membrane receptor(s) and the resulting complex is internalized through clathrin-mediated endocytosis ([@b0445]). Consequently, the capped viral genome is released from the virion during the uncoating process and directly translated by the host cell ribosomal machinery. The non-structural proteins thus generated allow for the replication of the viral genome (probably in specific viral replication complexes) and the production of subgenomic RNA that is translated into the structural proteins from ORF2 and ORF3. Full-length RNA progeny is assembled with ORF2 capsid protein into viral particles of 27--30 nm ([@b0040]) that are consequently released from the cell in a non-lytic fashion. During release, HEV particles probably acquire a lipid bilayer (envelope) and associated ORF3 protein that are removed later by bile salts and enteric proteases respectively ([@b0825], [@b0890]).Fig. 2HEV replication cycle. HEV particles first bind to heparan sulphate proteoglycans (HSPG) and are consequently transferred to an unknown functional receptor, thus mediating cellular uptake through clathrin-mediated endocytosis. Following uncoating, the viral RNA genome is released into the cytoplasm and translated into non-structural proteins. These proteins form a replication complex that produces new full-length and subgenomic viral RNA. The latter is translated into capsid protein (ORF2) and the membrane associated ORF3 protein that is known to interfere with interferon-α signaling. Viral RNA is packaged into capsid protein and released from the cell with help of the host factor Tumor susceptibility gene 101 (Tsg101). The released particles are associated with lipids and ORF3 proteins; both are consequently removed through the bile acids and digestive proteases respectively.

2.3. Genetic diversity {#s0025}
----------------------

HEV is classified into the *Hepevirus* genus in the family of the *Hepeviridae* ([@b0935]). At least 4 genotypes are currently recognized ([@b0790]); genotypes 1 and 2 solely infect humans while genotypes 3 and 4 are zoonotic agents with their main reservoir in domestic pigs ([@b0240], [@b0580], [@b0830]). Two additional genotypes have been proposed for HEV isolates from Japanese wild boars ([@b0790]). Several viruses that are more or less related to HEV have been isolated from different species, including chickens (avian HEV, [@b0335]), rabbits ([@b0915]), rats ([@b0385]), bats ([@b0215]), ferrets ([@b0705]) and trout ([@b0055]) ([Fig. 3](#f0015){ref-type="fig"} ). The exact classification of these viruses remains to be determined ([@b0790]) and future discovery of additional hepeviruses seems likely.Fig. 3HEV species and genotypes. The phylogenetic relationship of different human HEV genotypes and the reported animal strains was plotted with the Virus Pathogen Database and Analysis Resource (ViPR, [@b0670]) based on following sequences: HEV gt1 (GenBank accession No. [M80581](ncbi-n:M80581){#ir0005}), HEV gt2 ([M74506](ncbi-n:M74506){#ir0010}), HEV gt3 ([HQ389543](ncbi-n:HQ389543){#ir0015}), rabbit HEV ([FJ906895](ncbi-n:FJ906895){#ir0020}), HEV gt4 ([AB220973](ncbi-n:AB220973){#ir0025}), wild boar HEV 2006 ([AB602441](ncbi-n:AB602441){#ir0030}), wild boar HEV 2009 ([AB573435](ncbi-n:AB573435){#ir0035}), ferret HEV ([JN998606](ncbi-n:JN998606){#ir0040}), rat HEV ([GU345043](ncbi-n:GU345043){#ir0045}), bat HEV ([JQ001749](ncbi-n:JQ001749){#ir0050}), avian HEV ([AY535004](ncbi-n:AY535004){#ir0055}), CTV ([HQ731075](ncbi-n:HQ731075){#ir0060}). CTV, cutthroat trout virus; gt, genotype.

3. Hepatitis E {#s0030}
==============

3.1. Epidemiology of disease {#s0035}
----------------------------

HEV genotypes 1 and 2 only infect humans and are endemic in many developing regions where they tend to cause large-scale water-borne outbreaks ([@b0150], [@b0620]). Genotype 1 is mainly found in Asia and Africa ([@b0800], [@b0855]), while genotype 2 has been isolated from Mexico and Africa, but seems less common ([@b0545], [@b0865]) (see [Fig. 4](#f0020){ref-type="fig"} ). It is estimated that infections with these genotypes result in 70,000 deaths annually ([@b0720]). Genotypes 3 and 4 on the other hand are zoonotic agents with their main reservoir in domestic pigs ([@b0145], [@b0515], [@b0820]). Genotype 3 has a worldwide distribution, while genotype 4 is mostly found in Asia ([@b0595], [@b0880]). However, genotype 4 has also been isolated from European pigs and patients recently ([@b0320], [@b0375]). Genotype 3 and 4 infections often result from consumption of undercooked pig or deer meat and may thus cause sporadic cases of hepatitis E. Although exact epidemiological data are missing, these infections seem a lot more common than initially thought ([@b0155], [@b0370], [@b0870]).Fig. 4Geographic distribution of HEV genotypes 1--4. Countries with confirmed human infections are color-coded according to the detected genotype. This is probably an incomplete picture as there are no data available for many countries and genotyping is not always performed and/or reported.

3.2. Clinical syndromes {#s0040}
-----------------------

Acute hepatitis E is characterized by jaundice, fatigue, gastrointestinal discomfort, etc. and is clinically indistinguishable from for instance hepatitis A ([@b0475]), although many infections remain asymptomatic. Most cases of hepatitis E resolve spontaneously, but in some patients the infection may progress to fulminant hepatitis. Overall mortality rates are estimated between 0.5% and 4% (e.g. [@b0475], [@b0855]).

One particularly intriguing characteristic is that hepatitis E is often lethal in pregnant women with mortality rates of up to 20--25% ([@b0480], [@b0860]), although this has only been observed for genotype 1 infections. Increased frequencies of obstetric complications and stillbirths have also been reported ([@b0660]). The underlying mechanisms of this phenomenon (hormonal, immunological, genetical factors, etc.) are unclear to date.

A more recent finding is that HEV can establish chronic infections in immunocompromised subjects such as transplant and HIV-infected patients ([@b0140], [@b0160], [@b0410]). This has only been reported for genotype 3 thus far. Such chronic infections are rarely symptomatic and are sometimes mistaken for drug-induced liver injury ([@b0175]). Chronic hepatitis E may lead to cirrhosis in 10% of patients ([@b0435]) and can ultimately result in death.

Occasional extrahepatic manifestations have also been reported; these are mostly neurological complications such as Guillain--Barré syndrome and neuralgic amyotrophy ([@b0255], [@b0420], [@b0795]) or nefrological manifestations such as glomerulonephritis ([@b0440]).

As evident from the discussion above, hepatitis E is profoundly different from the well-known disease courses of hepatitis B and C. While a considerable portion of patients infected with the hepatitis B virus (HBV) and especially the hepatitis C virus (HCV) evolves to chronicity, spontaneous recovery is the rule for hepatitis E where chronic disease has thus far only been reported in immunocompromised patients. The high rate of mortality in pregnant women is also unique to hepatitis E and no similar phenomena have been reported for hepatitis A, B or C.

3.3. Diagnostic methods {#s0045}
-----------------------

The most frequently used tests for diagnosing hepatitis E are detection of IgM and IgG antibodies by enzyme-linked immunosorbent assays (ELISA) and detection of viral RNA by (quantitative) reverse transcription PCR (RT-PCR). Presence of IgM antibodies indicates a recent infection, while IgG antibodies appear later and persist afterwards, at least for some time, indicating a past exposure. The current ELISAs suffer from large variability between assays ([@b0060], [@b0220], [@b0575]) and therefore require urgent optimization and validation. Acute infection is usually confirmed by (quantitative) RT-PCR (e.g. [@b0390]), although these assays should be standardized as well to increase reliability.

Since the incubation and symptomatic periods for acute hepatitis E are only a few weeks, the successful use of antiviral drugs for acute cases of hepatitis E would depend on the availability of a rapid and inexpensive diagnostic test. Such test should also be easy to employ in resource-poor settings.

4. Current control strategies {#s0050}
=============================

4.1. Vaccines {#s0055}
-------------

Vaccination would be an effective strategy to prevent HEV infection. Recently, such a HEV vaccine based on a recombinant truncated capsid protein was approved in China (Hecolin®, [@b0925]). It remains unclear whether the manufacturer intends to obtain market approval in other countries as well. Another recombinant vaccine successfully completed phase 2 clinical trials in Nepal ([@b0770]), but further development was halted. Such vaccines may be useful as a prophylactic measure in high-risk patients such as immunocompromised patients and pregnant women. This would require specific clinical trials to demonstrate protective efficacy in these populations; to the best of our knowledge, such studies have not yet been reported for Hecolin®. However, the organization of large-scale vaccination campaigns against HEV may not be particularly cost-effective given the mostly benign course of infection in developing countries and the relatively low incidence in the developed world.

4.2. Other prophylactic measures {#s0060}
--------------------------------

Since HEV is transmitted feco-orally, sanitary measures are probably the most effective strategy available to prevent viral spread. This is especially the case for genotypes 1 and 2 that often occur in large water-borne outbreaks. Availability of clean drinking water and proper disposal of waste water would be effective control strategies. Genotypes 3 and 4 are mostly spread through contaminated food stuffs, such as the infamous French figatellu sausage made from uncooked pig liver ([@b0065], [@b0145]). Thorough heating effectively kills the virus and prevents infection ([@b0245]). Although ineffectively, HEV can also be transmitted via blood transfusion ([@b0090], [@b0135]), suggesting that screening of donor blood may be warranted. In addition, vertical transmission of HEV has been reported ([@b0485]), indicating that extra caution is required in pregnant women.

5. Why do we need antiviral drugs against hepatitis E virus? {#s0065}
============================================================

5.1. Current standard of care {#s0070}
-----------------------------

Chronic HEV infections in transplant patients can occasionally be resolved by decreasing immunosuppression, leading to spontaneous clearance in about 30% of the patients ([@b0435]). When this approach is unsuccessful and for other types of patients, there are generally 2 possibilities: the use of pegylated interferon-alpha (PEG-IFNα) or ribavirin. PEG-IFNα has been used successfully in liver transplant, kidney transplant and leukemia patients with chronic hepatitis E ([@b0025], [@b0310], [@b0415], [@b0425]). However, ribavirin seems to be the drug of choice in most cases with successful treatments being reported for multiple types of transplant patients ([@b0430], [@b0550], [@b0675], [@b0680]), but also for HIV and leukemia patients with chronic hepatitis E ([@b0290], [@b0625]). Acute hepatitis E seems to respond to ribavirin treatment as well ([@b0285], [@b0680]). In addition, the anti-HEV activity of both drugs has been confirmed *in vitro* ([@b0185]). Nevertheless, they need to be administered for at least 3 months and are known for their severe adverse effects. For PEG-IFNα for instance, this includes influenza-like symptoms and neuropsychiatric side effects ([@b0555]). Ribavirin on the other hand may induce severe anemia necessitating dose reductions ([@b0430], [@b0675]). These reductions may in turn lead to treatment failure ([@b0680]). One may deem such severe side effects acceptable in light of the severity of chronic hepatitis E (as is the case for chronic hepatitis C as well), but this is certainly not true when these drugs would be used for prophylaxis or to treat mild infections. In addition, both ribavirin and PEG-IFNα are contra-indicated in pregnant women and other specific patient populations, leaving no available treatment options for these people. Also when considering acute infections during large outbreaks in developing countries, PEG-IFNα is not an option due to the fact that parenteral administration is needed and the required follow-up of hematological parameters during ribavirin treatment is difficult to implement in such settings.

5.2. Future therapy for hepatitis E {#s0075}
-----------------------------------

For the reasons stated above, safe and effective treatments for hepatitis E are urgently required. In case of acute infections, antiviral drugs would be useful to shorten the period of illness and prevent progression to fulminant hepatic failure. Such application would require rapid diagnosis of hepatitis E (see also Section [3.3](#s0030){ref-type="sec"}). Another possibility would be to use antivirals to halt viral spread during epidemics and outbreaks. The fact that these outbreaks occur rather often in refugee camps (e.g. [@b0015]; [@b0100]) may represent an opportunity for clinical trials testing the prophylactic potential of HEV inhibitors if such studies would be appropriate from an ethical point-of-view.

In pregnant women, such drugs could be life-saving for both mother and child, on the condition that they are devoid of teratogenic and significant adverse effects. Ideally, these women should be screened regularly with a rapid and sensitive HEV test and treated as soon as possible. This may be difficult to implement in developing countries where genotype 1 is endemic, so an approved HEV inhibitor should be sufficiently potent to arrest an established (fulminant) infection. Modulation of the hormonal system may be another interesting therapeutic option (see suggestions in Section [7.6](#s0100){ref-type="sec"}), although the development of such strategy would require more detailed insights into disease pathogenesis.

For chronically infected patients, rapid clearance of HEV is required before irreversible progression to cirrhosis has occurred. Ideally, these drugs should be applicable in a diverse range of immunocompromised patients without overt toxicity. Since ribavirin treatment has a rather good efficacy in chronically HEV-infected patients, a combination regimen with another HEV-inhibitor could be envisaged (as is currently being explored for HCV: ribavirin + direct-acting antiviral(s), (e.g. [@b0645], [@b0910]). This may allow decreasing the ribavirin dosage, thus reducing and hopefully avoiding anemia and other side effects. In addition, we observed a slight synergistic effect *in vitro* for the combination of ribavirin and interferon-α ([@b0185]), suggesting that such a combination regimen may be worth considering in the clinical setting. Successful combination therapy has already been reported for a chronically HEV-infected HIV patient ([@b0170]).

Developing antiviral drugs for the treatment of HEV infections will commercially not be as rewarding as for instance the development of HCV inhibitors ([@b0190]). Therefore, it appears opportune to consider other strategies than the classical discovery-development of completely new chemical entities as well, for instance off-label use of drugs with robust anti-HEV activity that are registered for unrelated indications when such molecules would be identified.

6. Currently available methods for drug testing {#s0080}
===============================================

6.1. *In vitro* testing {#s0085}
-----------------------

Efficient cell culture systems for HEV have only recently become available. The Okamoto research group reported on both genotype 3 and 4 strains that replicate in PLC/PRF/5 (hepatoma) and/or A549 (lung adenocarcinoma) cell lines ([@b0825], [@b0835], [@b0840]). The PLC/PRF/5 cells were also employed in a 3D cell culture system for HEV ([@b0070]). On the other hand, the NIH research group of Emerson derived a passage 6 virus of the Kernow-C1 strain that replicates in Huh7 and especially HepG2/C3A hepatoma cells ([@b0775], [@b0780]). This strain is derived from a chronically infected patient and contains an inserted human ribosomal S17 RNA fragment in the hypervariable region ([@b0775]). Detailed analyses indicated that this fragment and several additional mutations contributed to the improved *in vitro* replication. Although the replication capacity of this strain is sufficient for virus yield assays (e.g. [@b0185]), overall growth kinetics are still rather slow. No cytopathic effect (CPE) has been described for any of these HEV strains, precluding the use of standard virology techniques such as CPE reduction assays and plaque assays. In addition, genotype 1 replicates only poorly in cell culture ([@b0635]) while it probably accounts for most of the human infections worldwide.

Several replicon constructs have also been established in which the 5′ part of the structural proteins is replaced by a GFP, neomycin resistance or luciferase gene ([@b0300], [@b0780]). The Kernow-C1 p6/luc reporter replicon proved especially useful in our hands as transient transfection into Huh7 cells allows for a 3-day antiviral assay to be performed ([@b0185]). For large-scale cell-based screenings with such replicons, a selectable reporter replicon would be highly convenient.

Another possible strategy to identify novel inhibitors of HEV replication is to use a surrogate virus. We recently reported that the cutthroat trout virus (CTV) may serve as such a surrogate ([@b0195]). CTV was isolated in 1988 from spawning trout in the western USA ([@b0345]) and recent studies revealed that the virus belongs to its own genus in the *Hepeviridae* family ([@b0790]). It has a remarkable similarity to HEV, especially when considering the helicase and polymerase sequences ([@b0055], [@b0195]). CTV replicates readily in cell culture allowing for RT-qPCR-based virus yield assays to be performed ([@b0195]). In addition, its *in vitro* replication kinetics can be further improved through repeated passaging (our unpublished results). In addition, CTV is a cytopathic virus. The CPE induced in CHSE-214 cells is rather limited, but we observed that nearly complete CPE can be attained in other piscine cell lines (our unpublished results). The avian HEV has also been successfully employed as a surrogate model (e.g. [@b0470], [@b0685]).

In conclusion, recent developments have considerably expanded the number of assays and tools available for HEV antiviral studies. However, the possibilities are still rather limited and the field would benefit from for instance HEV strains with improved replication kinetics, enzymatic assays for the different non-structural proteins and selectable reporter replicons.

6.2. Evaluation in laboratory animals {#s0090}
-------------------------------------

An ideal animal model for HEV would be a small inexpensive animal (preferably rodent) that can be infected with human HEV or at least a closely related virus and that develops acute hepatitis with a clear increase in liver markers and with high viral titers. Mortality is not required, although a lethal phenotype is highly useful for antiviral drug testing. An animal model that mimics the hormone-dependent effects observed in pregnant women would be a plus.

Several animal models are available for *in vivo* HEV studies (see [Table 1](#t0005){ref-type="table"} for an overview), but they all have certain limitations. For instance, chicken and trout can be used as experimental animal models when infected with avian HEV and CTV, respectively ([@b0075], [@b0350]). Since both viruses are only surrogates for human HEV, further validation of experimental results would be required in another model. Genuine HEV infections can be performed in pigs ([@b0250], [@b0325], [@b0740]) and non-human primates such as macaques and chimpanzees ([@b0230], [@b0585], [@b0690], [@b0900])., However, ethical concerns as well as practical issues may make such studies complicated. Rodents may present a more accessible model organism. For instance, laboratory rats can be experimentally infected with rat HEV, but contradicting reports have been published for the human HEV genotypes ([@b0530], [@b0535], [@b0695], [@b0930]). Successful infection of Balb/c nude but not C57BL/6 mice with HEV was reported ([@b0365], [@b0520]), while rabbits can be infected with rabbit HEV and certain genotype 4 strains ([@b0125]). Finally, infection of Mongolian gerbils with genotype 4 has also been reported ([@b0525]). Due to the large variability between published results, a robust model that has been evaluated by multiple laboratories has not yet been reported. In addition, none of these models resulted in a lethal phenotype. For the predominant genotype 1 HEV, primates are even the only available model at this time. Promising strategies towards a robust animal model may be infection of immunedeficient rats or mice with rat HEV, discovery studies for a murine HEV species, HEV infection of mice with chimeric human or porcine livers ([@b0590]) or establishment of transgenic mice with a human HEV receptor (when identified), as was done successfully for poliovirus ([@b0725]) and HCV ([@b0210]).Table 1Overview of reported animal models for HEV and surrogate viruses with reported pathology (gt, genotype; IFN, interferon; ALT, alanine transaminase).Animal modelVirus speciesCharacteristicsReferencesChickenAvian HEVSeroconversion, virus shedding, gross hepatic lesions, splenomegaly[@b0075]TroutCutthroat trout virusAvirulent, only detected during spawning, IFN induction[@b0350]PigHEV gt 3 and 4Seroconversion, virus shedding, histopathological damage[@b0245], [@b0250], [@b0325] and [@b0740]Macaque (rhesus, cynomolgus), chimpanzeeHEV gt 1--4Seroconversion, virus shedding, histopathological damage[@b0230], [@b0585], [@b0690] and [@b0900]  Rat (Wistar)Rat HEVSeroconversion, virus shedding, no alterations in ALT[@b0535]HEV gt 1, 3 or 4Not infectable[@b0535]  (Nude)Rat HEVSeroconversion, limited virus shedding, higher titers than in immunecompetent rats[@b0535] and [@b0695]HEV gt 3Not infectable[@b0530]  (Sprague--Dawley)Rat HEVSeroconversion, limited virus shedding, histopathological damage, no alterations in ALT[@b0695]HEV gt 1, 2 or 3Not infectable (after intravenous injection)[@b0695]HEV gt 4Seroconversion, virus shedding (after intrahepatic RNA inoculation)[@b0930]  Mouse (Balb/c nude)HEV gt 4Seroconversion, virus shedding, histopathological liver damage[@b0365]  (C57BL/6)HEV gt 1, 3 and 4Not infectable[@b0520]  RabbitRabbit HEVSeroconversion, virus shedding[@b0125]HEV gt 4Seroconversion, virus shedding, symptomatic hepatitis (only for H4-NJ703 strain)[@b0125]Mongolian gerbilHEV gt 4Virus shedding, slight histopathological liver changes[@b0525]

6.3. Clinical trials {#s0095}
--------------------

When a HEV inhibitor would be shown to be successful in a (surrogate) animal model and would have an excellent safety and pharmacokinetic profile, clinical studies would be the next stage in development. For these studies, one could consider treating chronically infected patients, possibly in a combination regimen with ribavirin. However, these patients may have multiple co-morbidities and there could be confounding factors such as concomitant drug use leading to drug-drug interactions. Since hepatitis E has a rather long incubation period and clinical symptoms are often apparent for several weeks, clinical studies could possibly be performed in an outbreak setting as well; in this way, both prophylactic and therapeutic efficacy may be assessed.

7. Potential drug targets {#s0100}
=========================

Below we present a selection of viral and host proteins may be attractive targets for antiviral therapy (see also [Table 2](#t0010){ref-type="table"} ).Table 2HEV-encoded proteins and their (putative) functions.HEV-encoded proteinsConfirmed functionsCrystral structure?ReferencesORF1Non-structural proteinsMethyltransferaseGuanyltransferase, guanine-7-methyltransferaseNo[@b0540]Papain-like cystein proteaseProteolytic processing of ORF1? Deubiquitinating activityNo[@b0460], [@b0655], [@b0665] and [@b0765]Hypervariable regionInfluences efficiency of viral RNA replication, host/cell type specificity?No[@b0685] and [@b0780]MacrodomainPoly-ADP-ribose-binding, weak ADP-ribose 1″-phosphohydrolase activityNo[@b0225]Helicase5′--3′ RNA unwinding, NTPase, RNA 5′-triphosphataseNo[@b0450], [@b0455]RdRpRNA-dependent RNA polymerase activityNo[@b0010] and [@b0715]  ORF2Capsid proteinYes (HEV-like particle)[@b0305] and [@b0895]  ORF3Interaction with multiple cellular proteins, including Tsg101, hemopexin,...Suppression of interferon-α signalingParticle egressNo[@b0280], [@b0710], [@b0815], [@b0205] and [@b0890]

7.1. Inhibitors of HEV entry {#s0105}
----------------------------

The entry of a virus particle into the host cell is a multi-step process that involves attachment of the virus to its receptor on the cellular membrane, internalization of the virion-receptor complex and subsequent uncoating of the viral capsid releasing the RNA genome into the cytoplasm. The functional HEV receptor is still unknown to date, although there are indications that genotype 1 may use a different receptor(s) than genotype 3 ([@b0635]). It was also found that HEV attaches to HSPGs, more specifically to 6-O-sulfated syndecan-1, which may account for its liver tropism ([@b0400]). It is hypothesized that HSPGs act as a highly abundant initial attachment receptor that binds HEV with relatively low affinity. In a second step, the virion probably transfers to a high-affinity functional receptor and the resulting complex is internalized. Structure determination of a HEV-like particle combined with mutation and cell binding studies have identified a receptor binding site on top of the P2 dimer that protrudes from the 2-fold axis of symmetry ([@b0895]). Interestingly, this site is homologous to the norovirus receptor-binding site that attaches to histo-blood group trisaccharides ([@b0305]). In addition, another sialic acid-binding site was found in the P1 region of the capsid protein ([@b0305]).

Despite the limited information that is available on HEV attachment and entry, several potentially interesting antiviral strategies can be derived from these data. First, the homology between the putative HEV and norovirus receptor-binding sites suggests that norovirus attachment inhibitors could possibly be interesting leads for further development into anti-HEV drugs. No confirmed norovirus entry inhibitors have been described to date, but two potentially interesting prototype molecules were designed through NMR binding studies ([@b0700]) and in a similar way, citrate was found to compete with histo-blood group saccharides for norovirus binding ([@b0330]), suggesting a promising role for glycomimetics. A second and possibly overlapping approach is to search for inhibitors of HEV attachment to HSPGs. Heparan sulfate and related molecules inhibit the attachment of multiple viruses, both *in vitro* and *in vivo* (e.g. [@b0020], [@b0095], [@b0510]). However, the clinical applicability of such molecules remains questionable and would require complete abolishment of any anticoagulative properties. Pentosan polysulfate is such an oligosaccharide derivative that is approved and marketed for pain relief in interstitial cystitis ([@b0180]). Given that this drug inhibits entry of multiple viruses ([@b0035], [@b0265]), it may be worthwhile to test it as a therapeutic option for hepatitis E, although it still has some anticoagulant properties ([@b0760]). Thirdly, it has been shown that a truncated ORF2 protein is capable of preventing HEV infection *in vitro* ([@b0340]). Through further truncation of this protein or otherwise mimicking the receptor-binding region of HEV, it would theoretically be possible to prevent virions from binding to their cellular receptor. To illustrate the feasibility of such an approach, we refer to Myrcludex-B which is a lipopeptide derived from the HBV envelope protein and efficiently inhibits HBV entry *in vitro* and *in vivo* ([@b0875]).

The strategies outlined above illustrate that the lacking of an identified receptor is an important hurdle for the identification and study of attachment, entry and uncoating inhibitors for HEV. Now that efficient cell culture systems are available (e.g. [@b0780]), this hiatus can and should be addressed.

7.2. RNA-dependent RNA polymerase inhibitors {#s0110}
--------------------------------------------

Following release of the viral RNA in the cytoplasm and initial translation, the RNA genome is replicated by an RNA-dependent RNA polymerase. Sequence alignments predicted an RdRp-encoding sequence at the 3′ end of ORF1 (see [Fig. 1](#f0005){ref-type="fig"}, [@b0495]) that belongs to the alphavirus-supergroup of RdRp's ([@b0490]). The polymerase activity was later confirmed by detection of newly synthesized negative-sense viral RNA *in vitro* ([@b0010], [@b0715]). The RdRp interacts with stem loops in the 3′ end of the viral genome and with the polyA-tail ([@b0010]) and co-localizes with the endoplasmatic reticulum ([@b0715]). However, further details about the HEV RdRp structure and function are missing.

As evidenced by the success of nucleoside and nucleotide inhibitors of HIV and herpesviruses, viral polymerases are attractive targets for antiviral therapy. Also the RdRp of RNA viruses has been targeted successfully by such molecules, consider for instance the nucleoside analogs that were developed against HCV, e.g. sofosbuvir is highly active, safe and has a high barrier to resistance. Sofosbuvir has successfully completed phase 3 clinical trials ([@b0505]) and may receive market approval in the near future. 2′-C-methylcytidine (2′CMC) is a related molecule and was the first nucleoside analog that entered clinical studies for the treatment of HCV infections. It has been shown to *in vitro* inhibit the replication of a number of other positive-sense single-stranded RNA viruses ([@b0395], [@b0730]). However, neither 2′CMC nor a number of its analogs exhibited significant activity in the transient HEV replicon assay (as described in [@b0185]), unpublished results). Also only moderate antiviral activity of 2′CMC was observed against CTV ([@b0195]). Despite these negative results, other nucleos(t)ide analogs may possibly be interesting inhibitors of HEV replication. Moreover, research efforts could be directed towards developing an RdRp inhibitor that targets both HEV and the distantly related alphavirus family. Such a broad-spectrum inhibitor would provide a much-needed treatment option for multiple infections by neglected viruses such as the Chikungunya virus, Sindbis virus and the equine encephalitis viruses. Elucidation of the HEV RdRp crystal structure and development of a convenient enzymatic assay would allow to jumpstart this specific domain of HEV antiviral research.

7.3. Methyltransferase inhibitors {#s0115}
---------------------------------

The HEV genome has a 5′ cap structure which is a crucial requirement for infectivity ([@b0230]). Capping is a multistep process involving hydrolysis of the γ-phosphate from the terminal nucleotide, subsequent conjugation to GMP resulting in a 5′-ppp-5′ triphosphate bond and finally methylation of the newly added guanosine. The 5′ proportion of the ORF1 sequence was predicted to encode a viral methyltransferase ([@b0495]) and indeed, the expressed protein displays guanyltransferase and guanine-7-methyltransferase activities ([@b0540]). The missing RNA triphosphatase function may be fulfilled by the HEV helicase ([@b0450]).

Since HEV is heavily dependent on the capping of its RNA genome for infectivity, the viral methyltransferase seems an ideal target for antiviral therapy, all the more since these enzymatic activities are virus-specific ([@b0540]) and thus may allow for development of selective inhibitors. Successful targeting of viral methyltransferases has been described for instance for dengue virus ([@b0045]) and West Nile virus ([@b0120]). Moreover, a highly efficient inhibitor of Chikungunya virus replication that selects for resistance mutations in nsP1 (viral methyltransferase) was recently identified in our laboratory (unpublished results; Delang L., Leyssen P. & Neyts J.); indicating that inhibition of this transferase may be a valuable strategy to inhibit the replication of RNA viruses, including HEV. Solving the crystal structure and development of robust enzymatic assays would be significant advances.

7.4. Helicase inhibitors {#s0120}
------------------------

RNA viruses require the RNA-unwinding activity of a virally encoded helicase enzyme for replication; the energy needed for this process is provided by the hydrolysis of NTPs ([@b0500]). As for the RdRp and methyltransferase, the NTPase and RNA unwinding activities of the predicted HEV helicase domain have been confirmed *in vitro* ([@b0455]). This helicase belongs to the 5′--3′ unwinding SF-1 helicase superfamily, which also comprises the alphavirus and coronavirus (CoV) helicases. Potent inhibitors have been identified for the SARS-CoV nsP13 helicase ([@b0005], [@b0845]), suggesting that it may also be possible to develop inhibitors of the HEV helicase. An important caveat is that such inhibitors need to be highly specific for viral helicases without affecting host helicase activity to avoid toxicity. Examples from the herpesvirus field (helicase-primase inhibitors such as letermovir which has successfully finished phase 2 clinical studies ([@b0565])) show that such selectivity can be attained.

7.5. Targeting other viral proteins {#s0125}
-----------------------------------

Besides the above mentioned enzymes, the HEV genome encodes several other proteins of which the function and significance have not been elucidated completely, like the macro domain, the viral protease and the ORF3 protein. Given that more information would become available, they may constitute suitable targets for antiviral therapy.

The macrodomain, formerly known as the X-domain, is located just upstream of the helicase gene ([Fig. 1](#f0005){ref-type="fig"}, [@b0495]). Its name is derived from the homologous non-histone domain of the macroH2A histone ([@b0225]). The exact function of the HEV macrodomain is unclear, although it strongly binds poly(ADP-ribose) ([@b0225]), an important post-translational protein modification involved in cell survival and apoptosis, among other functions ([@b0750]). Since it has been suggested that the biological function of viral macrodomains may be unrelated to that of their human homologs ([@b0630]), they could represent attractive targets for inhibition. However, this would require a more profound understanding of the function and activity of this domain.

Secondly, a papain-like cysteine protease domain has been predicted in the HEV genome sequence ([@b0495]), but it remains unclear whether this protease is fully functional. Consequently, one of the enigmas of HEV molecular biology is whether ORF1 is processed into discrete functional units or not: several publications reported processing of ORF1 to some extent ([@b0650], [@b0655], [@b0735], [@b0765]), while others found no processing whatsoever ([@b0030], [@b0665], [@b0810]). On the other hand, deubiquitination activity has been reported for the methyltransferase-protease fusion domain which may be involved in combating cellular antiviral responses ([@b0460]) and a recent mutational study suggested a glycine-triad as the protease substrate sequence ([@b0655]). Although viral proteases in general are interesting targets for antiviral therapy (as exemplified in the fields of HIV and HCV), more insight into the activity, function and structure of the HEV protease would be essential before focusing on protease inhibitors.

ORF3 encodes a 114 aa phosphoprotein ([@b0300]) that is exclusively found in hepeviruses. ORF3 protein is dispensable for *in vitro* infection of cultured cells ([@b0235]), but required for infection and seroconversion of rhesus macaques ([@b0295]). A number of functions have been proposed and several binding partners have been identified ([@b0360], [@b0710]), but in general, ORF3 protein seems to optimize the host cell for HEV replication by increasing cell survival ([@b0110], [@b0105], [@b0600]) and suppressing interferon-α signaling ([@b0205]). In addition, ORF3 protein has been implicated in virion egress ([@b0890]) and disruption of blood coagulation ([@b0280]). It should be noted that most of these results have been obtained in artificial systems, i.e. overexpression of ORF3 protein in cultured cells instead of genuine infection with HEV. In order to be targeted for antiviral development, more insight into the ORF3 structure and function is required. Since the protein has multiple cellular binding partners, it may be interesting to look for inhibitors of these protein--protein interactions (see also Section [7.6](#s0100){ref-type="sec"}). Such an approach may yield very specific inhibitors of HEV replication with low toxicity and a high barrier to resistance, especially given the overlap with ORF2 which is expected to substantially limit the number of viable mutations. The feasibility of identifying protein--protein interaction inhibitors as antiviral molecules was proven for the interaction between LEDGF/p75 and the HIV integrase for instance ([@b0130]).

7.6. Host factors {#s0130}
-----------------

Since many direct-acting antiviral agents are prone to the emergence and selection of resistant viruses, there is an increasing interest in targeting host factors that are co-opted by viruses for their own replication. Such host factor-targeting antivirals should have an increased barrier to resistance and may potentially have broad-spectrum activity. Multiple binding partners have been identified for HEV structural and non-structural proteins. The functional significance of many of these interactions remains unclear to date, but some of the host factors may be well-suited for antiviral targeting. Here, we discuss a few host factors that we believe have the most potential at being drugable.

First, tumor susceptibility gene 101 (Tsg101) is a central mediator in the endosomal protein sorting pathway ([@b0815]). HEV ORF3 protein has a PSAP-motif through which it associates with Tsg101, thus increasing secretion of the immunosuppressive α1-microglobulin and locally suppressing the host immune response ([@b0815]). In addition, Tsg101 is required for virion release by interacting with the ORF3 protein PSAP-motif ([@b0470], [@b0610], [@b0615]). The involvement of Tsg101 in virion release is not limited to HEV; it was also found to be essential for HIV and Ebola virus budding ([@b0270], [@b0570]) and is being explored as a target for antiviral therapy ([@b0115]). For instance, cyclic peptides blocking the interaction between Tsg101 and the PTAP motif of the HIV Gag-protein were found to block HIV budding ([@b0850]). Moreover, Tsg101 is expressed on the cell membrane during both HIV and influenza virus infection and targeting by antibodies blocks virus production ([@b0080], [@b0200]). Similar questions can be posed for HEV: does HEV induce expression of Tsg101 at the cell membrane? Can the interaction between Tsg101 and ORF3 be blocked with a small molecule or (cyclic) peptide? Potentially, antiviral research on HEV could piggy-back on the ongoing efforts for HIV and influenza virus and thus advance rapidly.

Another interesting finding is that the proteasome inhibitor MG132 inhibits HEV replication, indicating that HEV likely requires an active ubiquitin--proteasome system for infection ([@b0465]). Similar findings have been reported for influenza virus ([@b0315]), HIV ([@b0755]) and vaccinia virus ([@b0745]). This suggests that targeting the proteasome system may be an interesting strategy for identifying broad-spectrum antiviral drugs. Proteasome inhibitors such as bortezomib and carfilzomib are currently being used in the treatment of multiple myeloma, based on the increased susceptibility of cancer cells compared to non-malignant cells ([@b0355]). However, it is unknown whether such a selectivity can also be attained for virus-infected cells versus healthy cells to avoid severe side effects.

A similar analysis may apply to heat shock protein 90 (hsp90) as a cellular target for anti-HEV drugs and antiviral therapy in general. Hsp90 is required for intracellular trafficking of HEV particles and inhibition of hsp90 with geldanamycin blocks HEV infection ([@b0920]). Many viruses depend on hsp90 and their replication can be blocked by hsp90 inhibitors ([@b0050], [@b0275], [@b0805]). Such inhibitors are currently being developed as anticancer therapies ([@b0380] for an overview), but the question remains if sufficient selectivity can be attained for safe antiviral therapy. An alternative strategy may be to specifically inhibit the protein--protein interaction between the HEV capsid and hsp90, thus leaving hsp90 enzymatic activity undisturbed.

Finally, there are multiple indications that HEV replication may be influenced by sex hormones. First, mortality increases dramatically in pregnant women infected with genotype 1 (up to 25%, [@b0480], [@b0860]). The underlying mechanism is still unclear, but it is known that low progesterone receptor mRNA levels and mutations in the progesterone receptor gene (PROGINS) are associated with poor pregnancy outcome (fulminant hepatic failure, fetal and maternal death) during HEV infection ([@b0085]). On the other hand, autochthonous HEV infections in developed countries seem to primarily affect males over 50 ([@b0165], [@b0175], [@b0560]). We reported that the replication of the CTV, a HEV surrogate virus, can be directly influenced by different concentrations of progesterone, testosterone and 17β-estradiol ([@b0195]), suggesting the possibility of a similar phenomenon in HEV infection. Several potential strategies can be derived from the limited information that is available. Since decreased progesterone receptor activity is associated with poor pregnancy outcome in hepatitis E ([@b0085]) and high concentrations of progesterone inhibit CTV replication ([@b0195]), one may consider progesterone supplementation in pregnant women with hepatitis E. Such supplementation has been approved by the FDA for the prevention of preterm birth ([@b0640]). Similarly, testosterone levels decrease with age and low testosterone concentrations facilitate CTV replication ([@b0195]), suggesting that testosterone supplementation may be beneficial in elderly man (chronically) infected with HEV. A third possibility may be the use of selective estrogen receptor modulators (SERMs), such as tamoxifen and raloxifene. SERMs were found to inhibit HCV replication *in vitro* ([@b0605], [@b0885]) and raloxifene improved the efficacy of pegylated interferon + ribavirin in menopausal women chronically infected with HCV ([@b0260]). It would be interesting to look into the effects of SERMs on HEV or CTV replication as they may represent another possible treatment option for hepatitis E (but not during pregnancy). To fully explore the potential treatment of hepatitis E through modulation of the hormonal system, a robust animal model displaying hormone-dependent virus replication would be much appreciated.

8. Directions for future research {#s0135}
=================================

Antiviral drugs for the treatment of hepatitis E are required for both acute and chronic infections. Such drugs should have an increased potency, efficacy and safety compared to the currently used ribavirin and PEG-IFNα, thus allowing for prophylactic use, containment of outbreaks and preferably treatment of pregnant women and other high-risk patients as well. It would also be interesting to further characterize the mechanism of action of ribavirin and PEG-IFNα in hepatitis E. As evident from the discussion above, HEV is an understudied pathogen and most of the suggested antiviral strategies require a more elaborate fundamental knowledge of the molecular virology. In addition, better model systems should be developed, both *in vitro* and *in vivo*, for proper antiviral research to be conducted.

HEV is an extremely interesting pathogen that deserves more profound study. In the last decade, much effort has gone to the HCV antiviral field. As many (candidate) drugs are currently in advanced clinical development, awaiting market approval or even on the market, HEV research could potentially benefit from research groups switching their main focus from HCV to HEV.
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